Table 6. Prognosis-based staging system... | American Society of Hematology

Table 6.

Prognosis-based staging system in Waldenström macroglobulinemia

Stage	Risk group	Patients, %	Criteria	5-year OS, %^6-150	5-year PFS, %^6-151
A	Low	25	β2M < 3 mg/L + Hb ≥ 120 g/L	87	83
B	Medium	26	β2M < 3 mg/L + Hb < 120 g/L	63	55
C	Medium	28	β2M ≥ 3 mg/L + IgM ≥ 40 g/L	53	33
D	High	21	β2M ≥ 3 mg/L + IgM < 40 g/L	21	12

Stage	Risk group	Patients, %	Criteria	5-year OS, %^6-150	5-year PFS, %^6-151
A	Low	25	β2M < 3 mg/L + Hb ≥ 120 g/L	87	83
B	Medium	26	β2M < 3 mg/L + Hb < 120 g/L	63	55
C	Medium	28	β2M ≥ 3 mg/L + IgM ≥ 40 g/L	53	33
D	High	21	β2M ≥ 3 mg/L + IgM < 40 g/L	21	12

OS indicated overall survival; PFS, progression-free survival; and Hb, hemoglobin.

Estimated 5-year OS from initial registration.

Estimated 5-year PFS from treatment registration.